DROIA Ventures
Droia is a specialist investor, exclusively focused on the development of oncology and genetic disease therapies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed DROIA Ventures Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2020 | QurAlis | Series A | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 1/2022 | AmbAgon Therapeutics | Series A | 0 |
| 1/2017 | Cristal Therapeutics | Venture Round | 0 |
| 2/2020 | Montis Biosciences | Seed Round | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 7/2022 | Vicinitas Therapeutics | Series A | 65M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 1/2020 | PACT Pharma | Series C | 0 |
| 2/2020 | Volastra Therapeutics | Seed | 12M |
| 3/2023 | Volastra Therapeutics | Series A | 0 |
| 2/2018 | Convert Pharmaceuticals | Series A | 0 |
| 10/2019 | Cyteir Therapeutics | Series B | 40.2M |
| 1/2017 | OCTIMET Oncology | Series A | 12M |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 4/2020 | Accent Therapeutics | Series B | 0 |
| 4/2009 | NormOxys | Venture Round | 4.5M |
| 4/2021 | Volastra Therapeutics | Seed | 32M |
| 3/2018 | Cyteir Therapeutics | Series B | 29M |
| 9/2016 | Arcus Biosciences | Series B | 70M |
| 7/2022 | Vicinitas Therapeutics | Series A | 0 |
| 1/2022 | AmbAgon Therapeutics | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 4/2021 | Volastra Therapeutics | Seed Round | 0 |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 7/2020 | Vico Therapeutics | Series A | 0 |
| 5/2020 | QurAlis | Series A | 0 |
| 4/2020 | Accent Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
